Phaseline

Companies › Avistone Biotechnology

Avistone Biotechnology: clinical trials, targets and expected readouts

5 active drug programs in 14 registered trials: 8 Phase 1, 6 Phase 2; Oncology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
PLB1004
EGFR inhibitor
EGFRPhase 2Non-Small-Cell Lung Cancer; NSCLC (Non-small Cell Lung Cancer); Non-Small Cell Lung CancerNov 2026
Vebreltinib
MET inhibitor
METPhase 2Non-Small-Cell Lung Cancer; Clear Cell Sarcoma (CCS)Dec 2026
ANS014004–Phase 1Locally Advanced or Metastatic Solid TumorsApr 2027
ANS03
ROS1 and NTRK tyrosine kinase inhibitor
ROS1, NTRKPhase 1Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK AlterationDec 2027
ANS02–Phase 1Non-Small Cell Lung CancerJun 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07336732PLB1004Phase 2Non-Small-Cell Lung CancerOncologyNov 2026
NCT06015503PLB1004Phase 2NSCLC (Non-small Cell Lung Cancer)OncologyDec 2026
NCT06343064PLB1004Phase 1Non-Small-Cell Lung CancerOncologyDec 2026
NCT06343064VebreltinibPhase 1Non-Small-Cell Lung CancerOncologyDec 2026
NCT06307795ANS014004Phase 1Locally Advanced or Metastatic Solid TumorsOncologyApr 2027
NCT07153887VebreltinibPhase 2Clear Cell Sarcoma (CCS)OncologyJul 2027
NCT06574347PLB1004Phase 2Non-Small-Cell Lung CancerOncologyJul 2027
NCT06574347VebreltinibPhase 2Non-Small-Cell Lung CancerOncologyJul 2027
NCT07655622VebreltinibPhase 1Non-Small-Cell Lung CancerOncologyDec 2027
NCT06716138ANS03Phase 1Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK AlterationOncologyDec 2027
NCT06328439ANS014004Phase 1Locally Advanced or Metastatic Solid TumorsOncologyDec 2027
NCT06046495PLB1004Phase 1Non-Small Cell Lung CancerOncologyFeb 2028
NCT06827145VebreltinibPhase 2Non-Small-Cell Lung CancerOncologySep 2028
NCT07538804ANS02Phase 1Non-Small Cell Lung CancerOncologyJun 2029

Targets

EGFR (1) MET (1) ROS1 (1) NTRK (1)

Companies with the same targets

AstraZeneca Shanghai Henlius Biotech Johnson & Johnson (Janssen) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Chia Tai Tianqing Pharmaceutical Group Betta Pharmaceuticals Allist Pharmaceuticals Dizal Pharmaceuticals Pfizer Pierre Fabre Medicament

Companies built like this

Nanjing Sanhome Pharmaceutical Jiangsu Alphamab Biopharmaceuticals Pierre Fabre Medicament Teligene US Xuanzhu Biopharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.